Cognition Therapeutics, Inc.CGTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank40
3Y CAGR-35.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-35.1%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 12.04% |
| 2023 | 22.66% |
| 2022 | 63.28% |
| 2021 | 44.11% |
| 2020 | -10.38% |
| 2019 | 0.00% |